Breast Neoplasms Clinical Trial
— iMOVEOfficial title:
Innovative Smart-phone-enabled Health Coaching Intervention (iMOVE) to Promote Long-term Maintenance of Physical Activity Behavior in Breast Cancer Survivors: Study Protocol for a Feasibility Pilot Randomized Controlled Trial
| NCT number | NCT02620735 |
| Other study ID # | 13-6157-DE |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | December 2014 |
| Est. completion date | July 2019 |
| Verified date | July 2019 |
| Source | University Health Network, Toronto |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
While physical activity (PA) appears to play an important role in disease control and the promotion of long-term health and well-being of cancer survivors, the large majority of breast cancer survivors are not physically active. Addressing this problem requires exercise promotion and an additional method of supporting long term exercise adherence. In response, an innovative health coaching intervention which uses mobile technology (iMOVE) to promote long-term PA in breast cancer survivors (BrCa) was developed. Project description: 107 inactive BrCa survivors will be randomized to receive a 12-week exercise program (CONTROL) OR a 12 week exercise program plus a concurrent health coaching program (iMOVE) consisting of telephone-based coaching sessions and interactive software delivered through a smart-phone and Fit-bit (wearable fitness technology) (INTERVENTION). Information on the feasibility and acceptability of the methods and intervention and examine the impact on fitness (primary), patient-reported, anthropometric, and physical (secondary) outcomes will be collected. Impact and relevance: PA has increasingly been identified as a modifiable factor that has the potential to impact cancer outcomes and improve quality of life. iMOVE is an innovative intervention with the potential to promote and maintain physical activity for breast cancer survivors. This study will be the first step in the evaluation of iMOVE and will help to determine whether a larger randomized controlled trial is needed.
| Status | Completed |
| Enrollment | 114 |
| Est. completion date | July 2019 |
| Est. primary completion date | July 2019 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Within 2 years of completion of adjuvant therapy, with the exception of hormone therapy, for early stage (0-IIIA) BrCa - Baseline participation of < 60 min of weekly pre-planned PA - Physician permission for moderate PA participation 4)Able to read and write English - Able to attend in-person exercise training sessions and physiologic assessments at prescribed intervals. Exclusion Criteria: - Plans to join a weight-loss or exercise program within 9 months) - Current pregnancy or planned pregnancy within 9 months) - Planned surgery during study; 4) not willing to be randomized. |
| Country | Name | City | State |
|---|---|---|---|
| Canada | ELLICSR, Toronto General Hospital 200 Elizabeth St. | Toronto | Ontario |
| Lead Sponsor | Collaborator |
|---|---|
| University Health Network, Toronto | Canadian Breast Cancer Foundation |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Recruitment Rate | Based on CONSORT criteria, a screening log enables data collection on eligible consented (pre- and post-initial screen) and non-recruited participants with reasons for non-recruitment recorded. | Through study completion, average of 2 years | |
| Primary | Retention Rate | To optimize retention and prevent attrition, stability (with some flexibility) is aimed for with group exercise in terms of class time/location, combined with careful selection and training of Health Coaches, short referral times | Through study completion, average of 2 years | |
| Primary | Capture of Outcomes - proportion of participants from whom complete information is derived on clinical outcomes. | As another major facet of feasibility, we assess the proportion of participants from whom complete information is derived on clinical outcomes, at which assessment time-points and then document rates of missing data. This outcome is measured in terms of frequency of completion not in the units of the measures themselves. | through study completion, average of 2 years | |
| Primary | Treatment Implementation and Fidelity - length, number and quality of health coaching phone sessions | For the experimental group, health coaching session lengths/numbers are recorded. The health coach will document use of health coaching techniques and tools, and the barriers identified. Use of the health coaching software is stored on the secure server and will be used to measure and analyze self-report and health coach activity. | through study completion, average of 2 years | |
| Primary | Acceptability:Participants perceptions regarding their experience of the study and if they liked it | To assess acceptability and inform future refinement, telephone interviews will be conducted with a purposefully selected sub-sample of experimental participants following intervention completion. The goal of the qualitative interviews is: 1) to explore participant perspectives of feasibility/acceptability of the health coaching intervention, and 2) to gain an understanding of specific experiences/attitudes among those successful and unsuccessful at PA maintenance PA. An interpretive description qualitative methodology will be used to meet this objective [154]. We will purposefully select participants, ensuring equal representation from participants who report exercise behavior has increased or decreased or stayed the same. We anticipate interviewing between 6-10 participants per group. A record of participation in the latter will be kept to distinguish these participants from those who were not chosen to participate. The semi-structured interviews will be 45-60 minutes in length. | through study completion, average of 2 years | |
| Secondary | Change in Cardiorespiratory fitness - "VO2"(oxygen consumption) Peak (mlO2/kg/min) | assessed by a physician-supervised graded exercise test using the modified Bruce protocol[155]. Directly measured "VO2" peak (mlO2/kg/min) and anaerobic threshold (AT) is obtained using a metabolic cart ("Parvomedics Trueone 2400" - name of machine) with continuous gas exchange analysis during incremental treadmill walking to peak capacity. Subjects perform an incremental ramp test to the limit of tolerance. A ramp slope based on sex, age and physical fitness of subjects is set to facilitate a test duration of 10-15 minutes. The limit of tolerance is defined as the point at which subjects cannot maintain current speed (miles per hour) and incline (%) despite encouragement from the CEP/RKin. Blood pressure and arterial oxygen saturations are measured at rest and during exercise. Absolute and relative test termination criteria are based on standardized guidelines[156]. Absolute and relative test termination criteria will be based on standardized guidelines |
baseline, 12 week, and 36 weeks | |
| Secondary | Change in exercise frequency - Leisure-Time Exercise Questionnaire (LTEQ) | Leisure-Time Exercise Questionnaire (LTEQ)- assesses exercise frequency and intensity;; assesses indices of state anxiety | baseline, 12 week, and 36 weeks | |
| Secondary | Change in body mass index (kg/m2) | Body composition is assessed by body mass index (BMI). BMI is calculated using the participant's weight and height (BMI = weight [kg]/height [m]2). WC is measured with anthropometric tape according to protocols defined by the World Health Organization (tape placed horizontally mid-way between the bottom of the rib cage and the iliac crest) and body fat percentage is measured using bioelectric impedance analysis [156] . To assess musculoskeletal function, grip strength is measured with a Jamar Dynamometer using the standard protocol. | baseline, 12 week, and 36 weeks | |
| Secondary | Change in waist circumference (WC) (cm) | Waist circumference is measured using anthropometric tape according to protocols defined by the World Health Organization (tape placed horizontally mid-way between the bottom of the rib cage and the iliac crest) and is measured in cm. and body fat percentage is measured using bioelectric impedance analysis [156] . To assess musculoskeletal function, grip strength is measured with a Jamar Dynamometer using the standard protocol. | baseline, 12 week, and 36 weeks | |
| Secondary | Change in quality of life - Functional Assessment of Cancer Therapy-Breast (FACT-B) | Functional Assessment of Cancer Therapy - Breast (FACT-B) - assesses quality of life | baseline, 12 weeks, 36 weeks | |
| Secondary | Change in indices of anxiety - Spielberger's State-Trait Anxiety Inventory-State (STAI-S) | Assesses indices of state anxiety | baseline, 12 weeks, 36 weeks | |
| Secondary | Change in state of depressive symptoms - The Center for Epidemiological Studies-Depression Scale Short Form (CESD-SF) | The Center for Epidemiological Studies-Depression Scale Short Form (CESD-SF)- measures state of depressive symptoms | baseline, 12 weeks, 36 weeks | |
| Secondary | Change in breast cancer related fatigue - Functional Assessment of Cancer Therapy-Fatigue (FACT-F) subscale | Functional Assessment of Cancer Therapy-Fatigue (FACT-F) subscale - assesses BrCa related fatigue; | baseline, 12 weeks, 36 weeks | |
| Secondary | Change in breast cancer related physical symptoms - The Breast Cancer Prevention Trial (BCPT) Symptoms Scale | The Breast Cancer Prevention Trial (BCPT) Symptoms Scale - measures BrCa related physical symptoms; | baseline, 12 weeks, 36 weeks | |
| Secondary | Change in fear of recurrence - Fear of Recurrence Questionnaire (FRQ) | Fear of Recurrence Questionnaire (FRQ) - provides measures on a 5-point Likert scale concerning fear of cancer recurrence | baseline, 12 weeks, 36 weeks | |
| Secondary | Group cohesion measure - Physical Activity Group Environment Questionnaire (PAGEQ) | Physical Activity Group Environment Questionnaire (PAGEQ) will be used to measure group cohesion | 12 weeks | |
| Secondary | Change in body fat percentage (%) | Body fat percentage is measured using bioelectric impedance analysis(156). | baseline, 12 weeks, 36 weeks | |
| Secondary | Change in grip strength (kg of force) | To assess musculoskeletal function, grip strength is measured with a Jamar Dynamometer using the standard protocol. | baseline, 12 weeks, 36 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
| Active, not recruiting |
NCT03664778 -
Abbreviated Breast MRI After Cancer Treatment
|
||
| Recruiting |
NCT03144622 -
18F-FSPG PET/CT Imaging in Patients With Cancers
|
||
| Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
| Active, not recruiting |
NCT04568902 -
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
|
Phase 1 | |
| Completed |
NCT02860585 -
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03698942 -
Delphinus SoftVue™ ROC Reader Study
|
||
| Completed |
NCT00092950 -
Exercise in Women at Risk for Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02151071 -
The Breast Surgery EnLight and LightPath Imaging System Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02934360 -
TR(ACE) Assay Clinical Specimen Study
|
N/A | |
| Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
| Completed |
NCT02931552 -
Nuevo Amanecer II: Translating a Stress Management Program for Latinas
|
N/A | |
| Not yet recruiting |
NCT02876848 -
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
|
N/A | |
| Recruiting |
NCT02547545 -
Breast Cancer Chemotherapy Risk Prediction Mathematical Model
|
N/A | |
| Completed |
NCT02303366 -
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
|
Phase 1 | |
| Completed |
NCT02518477 -
Preventive Intervention Against Lymphedema After Breast Cancer Surgery
|
N/A | |
| Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A |